3 active not recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 3 |
Follow Hemangiosarcoma: new trials by email Literature Review of Hemangiosarcoma trials Research Report on Hemangiosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma Durvalumab, Oleclumab - Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 75 | 2020-11-26 | 2026-11-03 |
| Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 798 | 2017-01-30 | 2026-06-17 |
Carcinoma, Adenoid Cystic (2) · Carcinosarcoma (2) · Cholangiocarcinoma (2) · Gallbladder Neoplasms (2) · Neurofibrosarcoma (2) · Osteosarcoma (2) · Parathyroid Neoplasms (2) · Thyroid Neoplasms (2) · Vulvar Neoplasms (2) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Adenocarcinoma, Mucinous (1) · Adrenal Gland Neoplasms (1) · Adrenocortical Carcinoma (1) · Anus Neoplasms (1)
Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Connective Tissue (3) · Neoplasms, Connective and Soft Tissue (3) · Neoplasms, Vascular Tissue (3) · Adenocarcinoma (2) · Adnexal Diseases (2) · Adrenal Gland Diseases (2) · Biliary Tract Diseases (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2)
Nivolumab (2) · CTLA-4 Antigen (1) · Disulfides (1) · Immunoglobulin G (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · durvalumab (1)
Instituto do Cancer do Estado de São Paulo (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1)
United States (2) · Brazil (1) · Guam (1)
Camila MV Moniz, Doctor (1) · Neeta Somaiah (1) · Sandip P Patel (1)
PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790
P30CA016672 (1), U10CA180888 (1)